Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 67, Issue 6, 2008, Pages 880-884

  Puechal X ^a,k   Miceli Richard, C ^b   Mejjad, O ^c   Lafforgue, P ^d   Marcelli, C ^e   Solau Gervais, E ^f   Steinfeld, S ^g   Villoutreix, C ^h   Treves R ⁱ   Mariette, X ^b   Guillevin, L ^j  

^a Le Mans General Hospital   (France)

^b BICÊTRE HOSPITAL   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g ERASME HOSPITAL   (Belgium)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ LIMOGES UNIVERSITY HOSPITAL   (France)

^j Cochin University Hospital ^*  (France)

^k CENTRE HOSPITALIER DU MANS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; GLUCOCORTICOID; ILOPROST; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ESOPHAGUS CANDIDIASIS; FEMALE; HUMAN; INFECTIOUS PNEUMONIA; MALE; MEDICAL RECORD; PHYSICIAN; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SEPTICEMIA; SKIN MANIFESTATION; STAPHYLOCOCCUS INFECTION; SYSTEMIC RHEUMATOID VASCULITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASCULITIS;

ADJUVANTS, PHARMACEUTIC; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PREDNISONE; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 45149103277     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.081679     Document Type: Article

References (15)

1. Vollertsen RS, Conn DL, Ballard DJ, Ilstrup DM, Kazmar RE, Silverfield JC. Rheumatoid vasculitis: survival and associated risk factors. Medicine (Baltimore) 1986;65:365-75.
2. Puéchal X, Said G, Hilliguin P, Coste J, Job-Deslandre C, Menkès CJ. Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis: a clinicopathological and prognostic study of 32 patients. Arthritis Rheum 1995;38:1618-29.
3. Voskuyl AE, Zwinderman AH, Westedt ML, Vandenbroucke JP, Breedveld FC, Hazes JM. The mortality of rheumatoid vasculitis compared with rheumatoid arthritis. Arthritis Rheum 1996;39:266-71.
4. Flipo RM, Cardon T, Copin MC, Vandecandelaere M, Duquesnoy B, Janin A. ICAM-1, E-selectin, and TNF alpha expression in labial salivary glands of patients with rheumatoid vasculitis. Ann Rheum Dis 1997;56:41-4.
5. Matsunawa M, Isozaki T, Odai T, Yajima N, Takeuchi HT, Negishi M, et al. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum 2006;54:3408-16.
6. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 2002;41:1126-32.
7. Richter C, Wanke L, Steinmetz J, Reinhold-Keller E, Gross WL. Mononeuritis secondary to rheumatoid arthritis responds to etanercept. Rheumatology 2000;39:1436-7.
8. Garcia-Porrua C, Gonzalez-Gay MA. Successful treatment of refractory mononeuritis multiplex secondary to rheumatoid arthritis with the anti-tumour necrosis factor alpha monoclonal antibody infliximab. Rheumatology 2002;41:234-5.
9. Unger L, Kayser M, Nusslein HG. Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis 2003;62:587-8.
10. Armstrong DJ, McCarron MT, Wright GD. Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab. J Rheumatol 2005;32:759.
11. van der Bijl AE, Allaart CF, Van Vugt J, Van Duinen S, Breedveld FC. Rheumatoid vasculitis treated with infliximab. J Rheumatol 2005;32:1607-9.
12. Garcia-Porrua C, Gonzalez-Gay MA, Quevedo V. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis? J Rheumatol 2006;33:433.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
14. Scott DGI, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 1984;76:377-84.
15. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8.